The estimated Net Worth of Growth Fund Limited Partner... is at least $1.5 Million dollars as of 12 May 2020. Growth Partner owns over 800,000 units of Ayala Pharmaceuticals stock worth over $1,495,737 and over the last 4 years Growth sold AYLA stock worth over $0.
Growth has made over 1 trades of the Ayala Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Growth bought 800,000 units of AYLA stock worth $12,000,000 on 12 May 2020.
The largest trade Growth's ever made was buying 800,000 units of Ayala Pharmaceuticals stock on 12 May 2020 worth over $12,000,000. On average, Growth trades about 400,000 units every 0 days since 2020. As of 12 May 2020 Growth still owns at least 2,991,473 units of Ayala Pharmaceuticals stock.
You can see the complete history of Growth Partner stock trades at the bottom of the page.
Growth's mailing address filed with the SEC is 34 YERUSHALAIM ROAD, BEIT GAMLA, 6TH FLOOR, RA-ANANA, L3, 4350110.
Over the last 4 years, insiders at Ayala Pharmaceuticals have traded over $930,844 worth of Ayala Pharmaceuticals stock and bought 1,575,250 units worth $23,628,700 . The most active insiders traders include Growth Fund Limited Partner..., Murray A Goldberg, and Growth Fund Limited Partner.... On average, Ayala Pharmaceuticals executives and independent directors trade stock every 37 days with the average trade being worth of $102,203. The most recent stock trade was executed by Gary B. Gordon on 24 February 2021, trading 3,000 units of AYLA stock currently worth $15,480.
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Ayala Pharmaceuticals executives and other stock owners filed with the SEC include: